Aparna Pharmaceuticals is an API and finished-dose manufacturer based in India. It holds one valid CEP. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 12 September 2023 as VAI. Customs aggregates show $289K of exports covering 14 molecules to 4 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Hyderabad, India | Not on file |
| Srikakulam, India | 3012390454 |
| Molecule | Regulators | Docs |
|---|---|---|
| Clopidogrel | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| CDSCO (India) | 1 | None |
| US FDA | None | 1 |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $90K | 2 |
| 2025 | Not reported | $289K | 4 |
| 2024 | Not reported | $157K | 4 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Aparna Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free